Get the Stockscreener App
4.26
1.43%
0.06
After Hours:
4.26
Enlivex Ltd stock is traded at $4.26, with a volume of 59,358.
It is up +1.43% in the last 24 hours and down -50.18% over the past month.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
See More
Previous Close:
$4.20
Open:
$4.22
24h Volume:
59,358
Relative Volume:
1.44
Market Cap:
$71.70M
Revenue:
-
Net Income/Loss:
$1.24B
P/E Ratio:
0.1672
EPS:
25.475
Net Cash Flow:
$-31.80M
1W Performance:
-8.19%
1M Performance:
-50.18%
6M Performance:
-76.33%
1Y Performance:
-74.69%
1-Day Range:
$4.02
$4.32
1-Week Range:
$4.02
$5.08
52-Week Range:
$4.02
$31.50
Enlivex Ltd Stock (ENLV) Company Profile
Compare ENLV vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Ltd
|
4.26 | 70.69M | 0 | 1.24B | -31.80M | 25.48 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Enlivex Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Ltd Stock (ENLV) Latest News
Enlivex Therapeutics Ltd (ENLV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Enlivex Market Sentiment - Benzinga España
Enlivex Therapeutics Ltd (ENLV) Balance Sheet - TradingKey
Enlivex Therapeutics Ltd (ENLV) Cash Flow - TradingKey
Enlivex Therapeutics Ltd (ENLV) Income Statement - TradingKey
Enlivex Therapeutics Ltd (ENLV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enlivex Therapeutics Ltd (ENLV) Institutional Confidence - TradingKey
Enlivex Therapeutics Ltd (ENLV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enlivex Therapeutics Ltd (ENLV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enlivex(ENLV) Stock Options Chain | Quotes & News - Moomoo
Enlivex Therapeutics Ltd (ENLV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ENLV|Enlivex Therapeutics Ltd|Price:4.200|Chg%:-0.160 - TradingKey
Enlivex Ltd (1BT.DU) latest press releases and corporate news - Yahoo Finance UK
Enlivex Ltd (1BT.DU) stock price, news, quote and history - Yahoo Finance UK
Enlivex Ltd. (ENLV) Posts Modest Gains as Shares Consolidate Near SupportRisk Reward Setups - dars.gov.et
Enlivex Reveals $1.1 Billion RAIN Token Treasury and $66.16 NAV Per Share - The Globe and Mail
Enlivex Ltd. (ENLV) Rallies 1.71% – Testing Key Resistance at $5.0RVOL Spike - dars.gov.et
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion - The Manila Times
Enlivex (Nasdaq: ENLV) details $1.1B RAIN token holdings and NAV - Stock Titan
Enlivex’s Net Asset Value Per Share Was $66.16 on July 18 - Stock Titan
Enlivex Ltd. (ENLV) upgraded to buy: Here's why - MSN
Enlivex Therapeutics Ltd (ENLV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enlivex (ENLV) Receives RMAT Designation for Knee Osteoarthritis Treatment - GuruFocus
Enlivex Wins FDA RMAT Status for Allocetra in Age-Related Knee Osteoarthritis - TipRanks
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why - Yahoo Finance
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
FDA grants regenerative medicine designation to Enlivex therapy By Investing.com - Investing.com South Africa
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis - The Manila Times
FDA grants regenerative medicine designation to Enlivex therapy - Investing.com
Enlivex (ENLV) wins FDA RMAT designation for Allocetra in age-related knee osteoarthritis - Stock Titan
FDA flags Enlivex’s Allocetra as potential new option for painful knee osteoarthritis - Stock Titan
Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA - Investing.com Canada
Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023. - marketscreener.com
Enlivex: Performance & Quotes, ENLV Stock Price on Nasdaq Exchange - marketscreener.com
Enlivex: Dividend historical data and projections - marketscreener.com
Enlivex: Shareholders Board Members Managers and Company Profile | IL0011319527 - marketscreener.com
Enlivex Ltd. (ENLV) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity - 富途牛牛
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026 - marketscreener.com
ENLV Q4 2025 Earnings: Massive EPS Miss and Continued Cash Burn PressureFinal Results - DonanımHaber
Enlivex Sets 1-for-15 Reverse Stock Split Ahead of July 9 Nasdaq Debut - The Globe and Mail
Enlivex announces 1-for-15 reverse stock split effective Wednesday By Investing.com - Investing.com Nigeria
Enlivex Therapeutics outlines its immunotherapy approach as a clinical-stage biotech - Ad Hoc News
Enlivex (ENLV) Implements Reverse Stock Split - GuruFocus
Enlivex announces 1-for-15 reverse stock split effective Wednesday - Investing.com
Enlivex (Nasdaq: ENLV) enacts 1-for-15 reverse split and cuts share count - Stock Titan
Enlivex to shrink share count 15-to-1 on July 9 as Nasdaq trading continues - Stock Titan
Enlivex announces 1-for-15 reverse stock split effective July 9, 2026, adjusting shares and par value. - Pluang
ENLV Q4 2025 Earnings: Staggering EPS Miss as Company Reports Significant LossesMargin Improvement Report - dars.gov.et
Enlivex Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):